View in EDS

The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease - Authors' reply.

Saved in:
Bibliographic Details
Title: The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease - Authors' reply.
Authors: Shen Y; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Jia J; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Teng J; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Yang C; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China., Hu Q; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: huqiongyi131@163.com.
Source: The Lancet. Rheumatology [Lancet Rheumatol] 2025 Jul; Vol. 7 (7), pp. e460-e461. Date of Electronic Publication: 2025 May 13.
Publication Type: Letter
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101765308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2665-9913 (Electronic) Linking ISSN: 26659913 NLM ISO Abbreviation: Lancet Rheumatol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40378857
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease - Authors' reply.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shen+Y%22">Shen Y</searchLink>; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.<br /><searchLink fieldCode="AU" term="%22Jia+J%22">Jia J</searchLink>; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.<br /><searchLink fieldCode="AU" term="%22Teng+J%22">Teng J</searchLink>; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.<br /><searchLink fieldCode="AU" term="%22Yang+C%22">Yang C</searchLink>; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.<br /><searchLink fieldCode="AU" term="%22Hu+Q%22">Hu Q</searchLink>; Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: huqiongyi131@163.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101765308%22">The Lancet. Rheumatology</searchLink> [Lancet Rheumatol] 2025 Jul; Vol. 7 (7), pp. e460-e461. <i>Date of Electronic Publication: </i>2025 May 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101765308 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2665-9913 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226659913%22">26659913 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Rheumatol <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40378857
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S2665-9913(25)00110-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e460
    Titles:
      – TitleFull: The use of IL-1 and IL-6 inhibitors should be prioritised in Still's disease - Authors' reply.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shen Y
      – PersonEntity:
          Name:
            NameFull: Jia J
      – PersonEntity:
          Name:
            NameFull: Teng J
      – PersonEntity:
          Name:
            NameFull: Yang C
      – PersonEntity:
          Name:
            NameFull: Hu Q
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2025 Jul
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2665-9913
          Numbering:
            – Type: volume
              Value: 7
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: The Lancet. Rheumatology
              Type: main
ResultId 1